NCT02313220 - Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Obesity

Interventions

DRUG

Dapagliflozin

Oral use

DRUG

Exenatide

Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.

DRUG

Placebo

Oral and Subcutaneous use.

Trial Locations (1)

75185

Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University and Section for Diabetes and Endocrinology at the Uppsala University Hospital, Uppsala